Trials / Completed
CompletedNCT02392130
A Clinical Trial to Assess the Potential of LEO 130852A Gel to Reduce Steroid Induced Skin Atrophy on Healthy Skin
A Prospective, Randomised, Investigator-Blinded, Vehicle-Controlled, Phase I Clinical Trial With Intra-Individual Comparison of Treatments to Assess the Potential of LEO 130852A Gel to Reduce Steroid Induced Skin Atrophy on Healthy Skin
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- LEO Pharma · Industry
- Sex
- Male
- Age
- 25 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the effect of LEO 130852A gel 1% in maintaining skin thickness in healthy skin treated with steroid.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Clobetasol propionate 0.05% ointment | |
| DRUG | LEO 130852A gel 1% | |
| DRUG | LEO 130852A placebo gel |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2015-06-01
- Completion
- 2015-06-01
- First posted
- 2015-03-18
- Last updated
- 2025-02-24
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02392130. Inclusion in this directory is not an endorsement.